Business
Noxopharm (ASX:NOX) share price closes 21% higher after clinical milestone // The Motley Fool Australia
The Noxopharm Ltd (ASX: NOX) share price gained more than 21% today, surging in a last-minute buying frenzy to close at 83 cents.
Noxopharm is an Australian clinical-stage drug development company. Its Veyonda drug is being designed to support cancer patients undertaking chemotherapy or radiotherapy treatment.
Noxopharm share price rockets upon survival benefit results
The company announced today that it would present its latest research findings at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium later this week.
The research pertains to extending the lives of patients who have late-stage prostate cancer.
Noxopharm’s LuPIN study enrolled a total of 56 patients with metastatic…
-
Noosa News22 hours agoEnsure voices are heard – Proctor
-
Noosa News24 hours agoCity of Moreton Bay claims homeless people consented to having camps thrown away
-
Business20 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
General24 hours agoFederal politics live: Government says RBA rate cut decision about ‘pace, not direction’